MeSH term
Frequency | Condition_Probility | Animals | 54 | 0.0 |
Humans | 195 | 0.0 |
Algorithms | 2 | 0.0 |
*Aryl Hydrocarbon Hydroxylases | 42 | 5.0 |
Comparative Study | 30 | 0.0 |
Cytochrome P-450 CYP1A2/metabolism | 4 | 4.0 |
Cytochrome P-450 CYP2D6/metabolism | 3 | 7.0 |
Cytochrome P-450 Enzyme System/*metabolism | 32 | 6.0 |
Insects | 3 | 1.0 |
Kinetics | 46 | 0.0 |
Microsomes, Liver/*enzymology | 12 | 6.0 |
Mixed Function Oxygenases/metabolism | 5 | 3.0 |
Research Support, U.S. Gov't, P.H.S. | 48 | 0.0 |
*Steroid 16-alpha-Hydroxylase | 8 | 4.0 |
Steroid Hydroxylases/metabolism | 3 | 4.0 |
Antineoplastic Agents, Alkylating/*metabolism | 2 | 28.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 7 | 5.0 |
Enzyme Inhibitors/pharmacology | 12 | 0.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 5 | 7.0 |
Microsomes, Liver/drug effects/*enzymology | 5 | 11.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 4 | 8.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors/*metabolism | 4 | 22.0 |
Transfection | 9 | 0.0 |
Biotransformation | 16 | 2.0 |
Insecticides/*metabolism | 2 | 25.0 |
Isoenzymes/metabolism | 12 | 2.0 |
Oxidation-Reduction | 20 | 1.0 |
Recombinant Proteins/metabolism | 17 | 0.0 |
Solvents | 2 | 3.0 |
Spectrophotometry, Ultraviolet | 4 | 2.0 |
Substrate Specificity | 24 | 1.0 |
Cytochrome P-450 CYP2E1/metabolism | 3 | 6.0 |
Rats | 25 | 0.0 |
Dose-Response Relationship, Drug | 14 | 0.0 |
Half-Life | 2 | 0.0 |
Cells, Cultured | 21 | 0.0 |
Cyclophosphamide/*pharmacology | 2 | 15.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Enzyme Induction/drug effects | 13 | 3.0 |
Hepatocytes/*drug effects/enzymology | 6 | 42.0 |
Research Support, Non-U.S. Gov't | 90 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Base Sequence | 9 | 0.0 |
Cell Line | 18 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 8 | 11.0 |
DNA Primers | 6 | 0.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
Enzyme Induction/*drug effects | 2 | 11.0 |
Molecular Sequence Data | 12 | 0.0 |
Phenobarbital/pharmacology | 7 | 11.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 4 | 3.0 |
Xenobiotics/*pharmacology | 3 | 10.0 |
Aged | 26 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 11 | 7.0 |
Female | 51 | 0.0 |
Hepatocytes/*enzymology | 3 | 20.0 |
Rifampin/pharmacology | 7 | 11.0 |
Sensitivity and Specificity | 2 | 0.0 |
Catalysis | 10 | 1.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 4 | 3.0 |
Enzyme Inhibitors/*pharmacology | 6 | 0.0 |
In Vitro | 26 | 0.0 |
Isoenzymes/antagonists & inhibitors | 2 | 4.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 2 | 6.0 |
Quantitative Structure-Activity Relationship | 2 | 6.0 |
Cytochrome P-450 Enzyme System/chemistry/*metabolism | 3 | 16.0 |
Models, Molecular | 5 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 9 | 2.0 |
Mixed Function Oxygenases/*genetics | 2 | 1.0 |
Oxidoreductases, N-Demethylating/*genetics | 8 | 18.0 |
Tumor Cells, Cultured | 12 | 0.0 |
Drug Interactions | 10 | 0.0 |
Enzyme Inhibitors/administration & dosage/*pharmacology | 2 | 12.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors | 2 | 6.0 |
Thiotepa/*pharmacology | 2 | 100.0 |
Adolescent | 11 | 0.0 |
Adult | 35 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Child | 5 | 0.0 |
Child, Preschool | 4 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Infant | 2 | 0.0 |
Isoenzymes/*metabolism | 9 | 3.0 |
Male | 53 | 0.0 |
Middle Aged | 31 | 0.0 |
Species Specificity | 11 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis | 3 | 3.0 |
Microsomes, Liver/metabolism | 9 | 5.0 |
Area Under Curve | 6 | 1.0 |
Aryl Hydrocarbon Hydroxylases/*physiology | 3 | 50.0 |
Cross-Over Studies | 3 | 0.0 |
Liver/*enzymology | 5 | 1.0 |
Microsomes/metabolism | 7 | 5.0 |
Oxidoreductases, N-Demethylating/*physiology | 4 | 40.0 |
Chromatography, High Pressure Liquid | 19 | 1.0 |
Enzyme Induction | 9 | 1.0 |
Gene Expression | 10 | 0.0 |
Mass Fragmentography | 5 | 2.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics/metabolism | 3 | 20.0 |
Enzyme Inhibitors/metabolism/pharmacology | 2 | 10.0 |
Isoenzymes/biosynthesis/genetics/metabolism | 2 | 7.0 |
Mice | 18 | 0.0 |
Microsomes, Liver/enzymology | 14 | 6.0 |
Rats, Long-Evans | 2 | 4.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Microsomes, Liver/*metabolism | 13 | 7.0 |
Models, Chemical | 3 | 0.0 |
Oxidoreductases, N-Demethylating/*metabolism | 7 | 8.0 |
Clinical Trials | 3 | 0.0 |
Neoplasms/*therapy | 2 | 1.0 |
Pharmaceutical Preparations/*metabolism | 3 | 3.0 |
Structure-Activity Relationship | 5 | 0.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Risk Factors | 2 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Binding Sites | 6 | 0.0 |
Molecular Conformation | 3 | 1.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Blotting, Western | 15 | 0.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
Mixed Function Oxygenases/*metabolism | 7 | 5.0 |
Troleandomycin/pharmacology | 5 | 8.0 |
Mixed Function Oxygenases/biosynthesis/genetics | 2 | 20.0 |
Oxidoreductases, N-Demethylating/biosynthesis | 2 | 25.0 |
RNA, Messenger/biosynthesis/drug effects | 5 | 8.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 3 | 2.0 |
Receptors, Steroid/*metabolism | 2 | 3.0 |
Time Factors | 7 | 0.0 |
RNA, Messenger/biosynthesis | 5 | 0.0 |
Autoantigens/*immunology | 2 | 1.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Anticonvulsants/*pharmacology | 2 | 10.0 |
Phenytoin/pharmacology | 2 | 14.0 |
Mixed Function Oxygenases/physiology | 3 | 25.0 |
Oxidoreductases, N-Demethylating/physiology | 3 | 50.0 |
Rats, Inbred F344 | 2 | 0.0 |
Cytochrome P-450 CYP2D6/physiology | 2 | 28.0 |
Cytochrome P-450 Enzyme System/*physiology | 5 | 8.0 |
Gene Therapy/*methods | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
DNA, Complementary | 9 | 0.0 |
Exons | 2 | 0.0 |
Polymerase Chain Reaction | 8 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Cytochrome P-450 Enzyme System/*chemistry/*metabolism | 2 | 11.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Liver/metabolism | 7 | 0.0 |
Microsomes, Liver/enzymology/metabolism | 4 | 6.0 |
Phenotype | 5 | 0.0 |
Protein Binding | 7 | 0.0 |
Analgesics, Opioid/*metabolism | 2 | 40.0 |
Cytochrome P-450 Enzyme System/genetics/*physiology | 4 | 36.0 |
Epithelial Cells/enzymology | 2 | 5.0 |
Isoenzymes/antagonists & inhibitors/genetics/*metabolism | 2 | 14.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Oxidoreductases, N-Demethylating/*biosynthesis/genetics | 4 | 40.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Methylation | 4 | 0.0 |
Microsomes, Liver/*enzymology/metabolism | 4 | 13.0 |
Hydroxylation | 19 | 5.0 |
Microsomes, Liver/drug effects/enzymology | 6 | 6.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Dealkylation | 6 | 10.0 |
Cytochrome P-450 Enzyme System/metabolism | 7 | 2.0 |
Rats, Wistar | 6 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Organ Specificity | 3 | 0.0 |
Dexamethasone/pharmacology | 4 | 0.0 |
Immunoblotting | 6 | 0.0 |
Isoenzymes/genetics/metabolism | 3 | 2.0 |
Receptors, Glucocorticoid/metabolism | 2 | 3.0 |
Receptors, Steroid/metabolism | 4 | 9.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/metabolism | 2 | 5.0 |
Microsomes/enzymology/metabolism | 3 | 17.0 |
NADP/metabolism | 2 | 1.0 |
Microsomes | 3 | 21.0 |
Microsomes, Liver/drug effects/enzymology/*metabolism | 2 | 11.0 |
Combined Modality Therapy | 2 | 0.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics | 2 | 14.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 3 | 2.0 |
Receptors, Cytoplasmic and Nuclear/*biosynthesis/genetics | 2 | 20.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Transcription Factors/*biosynthesis/genetics | 2 | 2.0 |
Metabolic Clearance Rate | 3 | 0.0 |
Pharmaceutical Preparations/metabolism | 2 | 6.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 2 | 2.0 |
Microsomes/enzymology | 3 | 2.0 |
Microsomes, Liver/enzymology/*metabolism | 7 | 9.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Cytochrome P-450 CYP1A1/metabolism | 2 | 3.0 |
Enzyme Activation | 3 | 0.0 |
Glucocorticoids/pharmacology | 2 | 1.0 |
Oxidoreductases, N-Demethylating/metabolism | 2 | 3.0 |
Thiazoles/*pharmacology | 2 | 3.0 |
*Thiazolidinediones | 2 | 2.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Microsomes, Liver/drug effects/*enzymology/metabolism | 2 | 22.0 |
Estradiol/*metabolism | 2 | 3.0 |
Antimalarials/*metabolism | 2 | 25.0 |
Isoenzymes/genetics | 2 | 0.0 |
Ketoconazole/pharmacology | 3 | 3.0 |
Orphenadrine/pharmacology | 2 | 50.0 |
Regression Analysis | 2 | 0.0 |
Sesquiterpenes/*metabolism | 2 | 50.0 |
Recombinant Proteins/antagonists & inhibitors/metabolism | 2 | 4.0 |
Stereoisomerism | 5 | 1.0 |
Haplorhini | 2 | 0.0 |
Testosterone/metabolism | 2 | 1.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 3 | 6.0 |
Coumarins/metabolism | 2 | 8.0 |
Indoles/metabolism/pharmacology | 2 | 33.0 |
Cyclophosphamide/pharmacology | 2 | 5.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics/*metabolism | 3 | 18.0 |
Liver/drug effects/enzymology | 2 | 3.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
Xenobiotics/*metabolism | 3 | 5.0 |
B-Lymphocytes/enzymology | 3 | 8.0 |
Aryl Hydrocarbon Hydroxylases/metabolism | 2 | 4.0 |
English Abstract | 4 | 0.0 |
Alleles | 2 | 0.0 |
Haplotypes | 3 | 0.0 |
Rabbits | 6 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 4 | 3.0 |
Cytochrome P-450 Enzyme System/genetics | 3 | 2.0 |
Genotype | 6 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
B-Lymphocytes/metabolism | 2 | 1.0 |
Mixed Function Oxygenases/antagonists & inhibitors/metabolism | 2 | 10.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Steroid Hydroxylases/*metabolism | 2 | 6.0 |
Lung/*enzymology | 2 | 3.0 |
Phenytoin/*pharmacology | 2 | 22.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Mixed Function Oxygenases/genetics/*metabolism | 2 | 4.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Isoenzymes/genetics/*metabolism | 4 | 4.0 |
Transcription, Genetic | 4 | 0.0 |
Antineoplastic Agents, Hormonal/*metabolism | 2 | 50.0 |
Estrogen Antagonists/*metabolism | 2 | 33.0 |
Aryl Hydrocarbon Hydroxylases/genetics/*metabolism | 2 | 8.0 |
Genes, Reporter | 3 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Receptors, Steroid/genetics/metabolism | 2 | 20.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/*metabolism | 2 | 25.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 2 | 5.0 |
Phosphodiesterase Inhibitors/*metabolism | 2 | 66.0 |
Analysis of Variance | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics/metabolism | 3 | 16.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 2 | 6.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 2 | 4.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 3 | 16.0 |
Prodrugs/*pharmacokinetics | 2 | 18.0 |
Styrene | 3 | 42.0 |
Styrenes/*metabolism | 2 | 100.0 |
Toluene/*metabolism | 2 | 25.0 |
Cyclophosphamide/*pharmacokinetics | 2 | 66.0 |
Xenobiotics/*pharmacokinetics | 2 | 12.0 |
Methoxychlor/*metabolism | 2 | 40.0 |
Enzyme Inhibitors/*metabolism | 2 | 2.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis | 4 | 25.0 |
DNA, Complementary/biosynthesis/genetics | 3 | 6.0 |
Oxidoreductases, N-Demethylating/*biosynthesis | 3 | 16.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Ethylene Glycols/metabolism | 2 | 40.0 |
Hepatocytes/enzymology | 2 | 13.0 |
Mixed Function Oxygenases/*physiology | 2 | 6.0 |
Fluorometry | 2 | 2.0 |
Variation (Genetics) | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis/*genetics | 2 | 66.0 |
Oxidoreductases, N-Demethylating/*biosynthesis/*genetics | 2 | 66.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
HL-60 Cells | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis/genetics | 3 | 18.0 |
COS Cells | 2 | 0.0 |
Down-Regulation/drug effects | 2 | 0.0 |
DNA, Complementary/biosynthesis | 2 | 3.0 |
Ligands | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Xenobiotics/pharmacology | 2 | 8.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
